Bill > HR3042

This bill, known as the MMEDS Act of 2025, aims to revitalize domestic medical manufacturing by providing significant tax incentives for companies establishing or expanding medical manufacturing facilities in economically distressed zones. The bill creates a new tax credit that allows eligible manufacturers to receive up to 40% credit against their taxes for wages, employee benefits, and facility investments in these zones. For manufacturers relocating production from foreign countries or producing population health products, the tax credit can increase to 60%. An "economically distressed zone" is defined as a census tract with a poverty rate of at least 25-30% over five years, with specific application and designation processes outlined. Additionally, the bill expands definitions and strategic initiatives related to population health products, focusing on developing medical products that can help vulnerable populations during pandemics or epidemics. The legislation also requires a report examining the health disparities experienced by various vulnerable populations and assessing the need for additional incentives to develop population health products. The tax incentives and provisions are designed to encourage domestic medical manufacturing, strengthen national supply chains, and support the development of medical products that can protect at-risk populations during health emergencies.

Budget and Finance

https://www.congress.gov/bill/119th-congress/house-bill/3042/all-info